← Evidence map

ArticlePharmaceuticals (Basel, Switzerland)2026

Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.

Maral Martin Mıldanoğlu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy. | OpenQuestion